Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients

Objectives: To investigate the factors influencing imipenem/cilastatin (IMI) and meropenem (MEM) concentrations in critically ill adult patients and the role of these concentrations in the clinical outcome. Methods: Plasma trough concentrations of IMI and MEM were detected by high-performance liquid...

Full description

Bibliographic Details
Main Authors:	Xi You, Qing Dai, Jing Hu, Mingjie Yu, Xiaowen Wang, Bangbi Weng, Lin Cheng, Fengjun Sun
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Journal of Global Antimicrobial Resistance
Subjects:	Imipenem/cilastatin Meropenem Therapeutic drug monitoring Drug resistance Clinical outcome
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716524000092

Similar Items

In vitro study of the embolic characteristics of imipenem/cilastatin particles
by: Hiroki Nakamura, et al.
Published: (2024-03-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
by: Paul Laffont-Lozes, et al.
Published: (2024-10-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
by: Takahiro Arima, et al.
Published: (2022-01-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
by: Shakila Baei Lashaki, et al.
Published: (2025-05-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
by: Telma de Sousa, et al.
Published: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
by: Sakiko Hiraki, et al.
Published: (2023-03-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
by: Takaki Hirano, et al.
Published: (2022-12-01)

Integrative greenness, blueness and whiteness determination of analytical RP-HPLC method for identifying Imipenem, Cilastatin and Relebactam in combined tablet form followed by forced degradation studies
by: Revathy Sundara Moorthy, et al.
Published: (2024-12-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
by: I. I. Shteynberg, et al.
Published: (2015-03-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
by: Peng Jia, et al.
Published: (2025-02-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
by: Ryan K. Shields, et al.
Published: (2024-06-01)

Overview and Insights into Carbapenem Allergy
by: Yuman Lee, et al.
Published: (2019-08-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023-01-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
by: Pasquale Sansone, et al.
Published: (2024-05-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
by: Sakiko Hiraki, MD, et al.
Published: (2023-09-01)

Corrigendum to “Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients” [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]
by: Xi You, et al.
Published: (2024-03-01)

Detection of aztreonam, meropenem and imipenem resistant Gram negative bacteria from inpatient department in Federal Medical Center (FMC), Birnin, Kebbi, Nigeria
by: Bilyaminu Jega, et al.
Published: (2024-02-01)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
by: Cristiana Leanza, et al.
Published: (2024-07-01)

Efficacy and safety of novel carbapenem–β-lactamase inhibitor combinations: Results from phase II and III trials
by: Wei Yu, et al.
Published: (2022-09-01)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates
by: Angeliki Kontou, et al.
Published: (2023-06-01)

Therapeutic drug monitoring of six contraindicated/co-administered drugs by simple and green RP-HPLC-PDA; application to spiked human plasma
by: Nada Hesham, et al.
Published: (2024-04-01)

Pharmacokinetic analysis of meropenem therapeutic drug monitoring data (TDM) in critically ill adult patients
by: I. B. Bondareva, et al.
Published: (2022-03-01)

Effectiveness and Nephrotoxicity of Loading Dose Colistin–Meropenem versus Loading Dose Colistin–Imipenem in the Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection
by: Wasan Katip, et al.
Published: (2022-06-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
by: Gan Y, et al.
Published: (2023-06-01)

Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties
by: Kang Luo, et al.
Published: (2019-06-01)

C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
by: Yichang Zhao, et al.
Published: (2022-05-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
by: Mona I. Shaaban, et al.
Published: (2017-04-01)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
by: Sergey Zyryanov, et al.
Published: (2023-03-01)

Comparison of Imipenem prescription model in Imam Khomeini and Taleghani Educational Center of Urmia
by: Maryam Divanbeygi
Published: (2024-01-01)

Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia
by: Chen Y, et al.
Published: (2024-02-01)

High adsorption capacity of hemoperfusion on imipenem in critically ill patients with septic shock: a case report
by: Chuhui Wang, et al.
Published: (2024-08-01)

Phenotypic detection of Metallo-β-Lactamase in imipenem-resistant Pseudomonas aeruginosa and Stenotrophomonas maltophilia at Schiphra Hospital of Ouagadougou in Burkina Faso
by: Boukaré Kaboré, et al.
Published: (2022-02-01)

Validation of Novel High-Performance Liquid Chromatography Method for Meropenem Quantification in Plasma
by: Aleksandar Rančić, et al.
Published: (2024-04-01)

The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance
by: Chiaki Ikenoue, et al.
Published: (2024-02-01)

Drug Utilization Evaluation of Imipenem in Patients Undergoing Bone Marrow Transplantation
by: Elnaz Sakhaiyan, et al.
Published: (2009-06-01)